Immunophotonics, Inc. announced two important milestones supporting the company’s continued advancement of Interventional Immuno-Oncology®: the closing of more than $10 million in Series C financing and the appointment of Robert H. Arch, Ph.D., as President and Chief Executive Officer. The financing reflects the continued confidence of the company’s investors in its science, strategy, and team....
Immunophotonics has strengthened its global intellectual property portfolio with the issuance of a patent by the China National Intellectual Property Administration (CNIPA). The patent covers the use of the company’s lead asset, IP-001, in combination with checkpoint inhibitors for the treatment of solid tumors. This milestone extends protection of Immunophotonics’ proprietary platform technology into a...
Markus Joerger, M.D., Ph.D. will present new data from a multi-center Phase 1b/2a clinical trial of IP-001 at the American Society of Clinical Oncology (ASCO) Annual Meeting during a poster session on May 30, 2026. The results add to growing momentum in immuno-oncology and further support Immunophotonics’ strategy of converting local tumor treatment into systemic...
Immunophotonics is excited to announce that the European Patent Office has issued a new patent titled “Semi-Synthetic Biopolymers for Use in Stimulating the Immune System.” This patent, which provides Immunophotonics with exclusivity extending into 2039 for this use, is now valid in over 20 European countries and covers the use of our lead drug candidate, IP‑001, in combination with checkpoint inhibitors for the treatment of...
We are excited to welcome Richard Levenson, M.D. to further strengthen our leadership team as a member of the Board of Directors of Immunophotonics, Inc. Dr. Levenson is a Professor of Pathology at UC Davis, internationally recognized for his pioneering work in medical imaging, cancer diagnostics, and translational research. His career spans academia and industry. His innovations in multispectral imaging,...
We’re entering an exciting new chapter at Immunophotonics as we announce key leadership transitions. After more than 15 years of visionary leadership, Lu Alleruzzo will be stepping down as CEO. Lu will continue to serve as a director and co-founder, working closely with Dr. Tomas Hode, our co-founder and Chief Innovation Officer, to advise the...
Over the past 15+ years – it has been my honor to help build Immunophotonics from its earliest vision into a company with great science, a strong global network and a mission that matters deeply to patients and clinicians. As we prepare for the next chapter of growth, I am excited and proud to welcome...
Immunophotonics announced the completion of the SAKK 66/17 Phase 1b/2a multicenter clinical trial, conducted in collaboration with the Swiss Cancer Institute. This marks a major step forward in evaluating the immunologically mediated anticancer effects of IP-001, our proprietary immune-stimulating drug, following thermal ablation in patients with advanced solid tumors. The trial assessed both safety and...
Immunophotonics has reached a major milestone in its clinical development efforts with the completion of treatment for the final patient in the INJECTABL-1 Phase 1b/2a trial of IP-001 for advanced solid tumors. The 41-patient, multicenter trial was conducted across the U.S., UK, France, Germany, and Switzerland, targeting colorectal cancer, non-small cell lung cancer, and soft...
Immunophotonics, Inc. has strengthened its leadership team with the appointment of Jacqueline Hess to its Board of Directors. With over 30 years of experience in leading and advising heavily regulated businesses that leverage the trans-Atlantic corridor as part of their growth journey, Ms. Hess joins an already-robust slate of directors currently serving on the Board...
